Programme for Pha

1. Now in it’s 4th Year and in Partnership with ISBER, Global Register and pay by
Biobanking has welcomed: Over 250 Attendees from Over
175 Different Organisations
1st July to save up to £400
In partnership
Biobanking, Biomarkers and Bioethics:
Establishing Partnerships and Improving Excellent content - very valuable
Biobanking to Further Medical Research National Cancer Institute
Conference: 27th-28th September
Biomarkers & Personalised Healthcare Focus Day: 29th September
Venue: Thistle Marble Arch, London, UK
19+ International Experts from
TOP 3 Reasons to attend Europe’s leading industry forum: Industry, Academia and National
Exclusive experiences and brand new case studies from industry, Biobanks
academia and national biobanks – bringing together all the key
stakeholders in one location Amelia Warner, Head of Clinical Pharmacogenetics, Merck
and the I-PWG
Officially partnered with ISBER to bring you the best programme,
speakers and expertise. Come away with real take-home messages you Xavier Briand, Team Leader, Biobank, Novartis
can use as soon as you get back!
Anne Bahr, Deputy R&D and Data Privacy Officer,
Brand new must-attend Focus Day on Biomarkers and Personalised sanofi-aventis
Healthcare brings even more networking and learning opportunities!
Arndt Schmitz, Senior Scientist, Bayer
Attending Biobanking 2011 will ensure you can: Bas de Jong, Biobank Manager, Erasmus MC Tissue Bank
and ISBER
Improve sample storage capabilities and quality through collaboration with new
expertise from Frans van der Horst, Chair, Dutch Collaborative Biobank and Georges Delphine Lagarde, Head of Biorepository, Roche
Dagher of INSERM and the BBMRI
Gillian Ellison, Tumour Genetics Capability Manager,
Enable greater sharing of data and specimens and improve biomarker research by AstraZeneca
establishing international biobanking standards and procedures with insights from Kim Myers,
Agostino Steffan, Director Clinical Pathology Unit, National
Director, U.S. National Cancer Institute
Cancer Institute (Italy)
Establish, develop and maintain a coordinated global biobanking network with new
Martin Armstrong, Associate Director, Translational
case studies from Xavier Briand, Team Leader, Biobank, Novartis and Delphine Lagarde, Medicine, Shire Pharmaceuticals
Head of Basel Sample Repository, Roche
Ruth Chadwick, Council Member, HUGO and Professor at
Successfully navigating the bioethical complexities and constraints of sample Cardiff University
collection and management to drive international harmonisation and enhance public
education, with examples and experiences from international bioethics experts Dr. Nik Zeps, Nik Zeps, Research Group Leader, St John of God
Prof. Ruth Chadwick and Prof. Bartha Knoppers Healthcare
Increase the effectiveness of medical and biomarker research by improving sample Georges Dagher, Deputy Director, Clinical Research, INSERM
quality through careful sourcing and management; discussions led by Bayer, AstraZeneca and Leader of Funding & Financing at BBMRI
and Merck
Antje Stratmann, Scientist, Bayer
www.globalbiobanking.com Emma Donald, Senior Research Scientist, AstraZeneca
New for 2011: Biomarkers and Personalised Bartha Knoppers, Director, Centre of Genomics and Policy,
McGill University
Healthcare Focus Day
Vincenzo Canzonieri, Co-Director, National Cancer
Effective biomarker research is not only key to better medical
Institute (Italy)
development but also the gateway to personalised healthcare.
That’s why this year’s event brings you: Kim Myers, Program Manager, U.S. National Cancer Institute
• 5 exclusive plenary sessions dedicated to biomarkers & person
alised healthcare Frans van der Horst, Chair, Dutch Collaborative Biobank
• An open panel discussion with the day’s international Speaker faculty
• Networking opportunities with peers and experts in this important field Lorenzo Memeo, Director of Pathology, Mediterranean
Institute of Oncology
Sponsors +44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk

2. Conference Day One: 27th September 2011
08:30 Registration and Refreshments 12:20 Networking Lunch Break
09:00 Chairman’s Welcome 13:40 Meeting the Need for Standardised Biobanking: The
U.S. National Cancer Institute’s Effort to Build a
IMPROVING BIOBANKING GLOBALLY: PARTNERSHIPS, Centre for Biospecimen Science and Standards
STANDARDS AND HARMONISATION • Justifying and building the centre and setting it’s
mission statement and goals
09:10 Keynote Session: The Importance and Role of • Building upon the National Cancer Institute’s
Collaborations in Biobanking Today history and experience in biospecimen
• Giving a brief insight into the history and role of management and science
the BBMRI • Identifying and prioritising the key areas in
• Discussing how the tremendous progress in biobanking which need standardisation most
the development of new analytical technologies • Using collaborations and partnerships to design
represents a major challenge for the future the standards and spread the message
development of medical research Kim Myers, Program Manager, U.S. National Cancer
• Evaluating the need for an efficient solution Institute
to providing trans-national access to high quality
human biological samples CONSIDERATIONS AND TOOLS TO ENSURE THE EFFECTIVE
• Looking at the BBMRI Expert Centres; private- AND EFFICIENT RUNNING OF YOUR BIOBANK
public partnerships could be an adequate solution
to these issues 14:20 Case Study: Effective Biobanking at Novartis -
George Dagher, Deputy Director, Clinical Research, Current Activities and Future Directions
INSERM and Leader of Funding & Financing at BBMRI • Coordinating studies and sample connection
effectively
09:50 The Benefits, Need and Practical Viability of Local or • Assessing the pro’s, cons and general use of
International Harmonised Biobanking automation in Novartis
• Assessing the need for multi-centre research to • Tracking samples from source to storage to
allow sample and data exchangeability research
• Discussing the need for harmonisation and • Improving healthcare: human samples for research
collaboration, and ISBER’s role in it - the Translational Research Initiative
• Evaluating internal vs external quality assurance Xavier Briand, Team Leader, Biobank, Novartis
(EQA)
• Predicting the effects of EQA on overall biobank 15:00 Networking Coffee Break
quality and credibility
• Standardisation in tissue collections; locally and 15:30 Case Study: Developing and Maintaining the Roche
across networks Sample Repository
Bas de Jong, Biobank Manager, Erasmus MC Tissue • Assessing the challenges, changes and
Bank and ISBER developments over the last 12 months
• Evaluating the SOPs and techniques for sample
10:30 Networking Coffee Break collection and preparation for storage
• Discussing the best methods of sample storage
11:00 Improving Sample Storage Capabilities and Quality • Using consent effectively and with minimal impact
through Collaboration on the biorepository
• Working together with a network of general Delphine Lagarde, Head of Basel Sample Repository,
hospitals to increase the scale of biobanking to Roche
increase quality and cost efficiency
• Building a centralised facility to support small 16:10 Biobanking Requirements for Third Party Providers:
scale participants An Industrial Perspective
• Deploying user-friendly web based applications • Outsourcing of all biobanking, sample handling and
(Bioresearch as a Service) to facilitate local biobank
preparation is one model for the pharmaceutical
initiatives
• Adopting generally accepted ontological sector
frameworks for information input to ensure • Highlighting and discussing the main requirements
optimal down stream data utilisation and accessibility • Assessing the expectations of providers from an
Frans van der Horst, Chair, Dutch Collaborative industry (personal) perspective
Biobank • Working together in order to achieve maximum
biobanking efficiency and effectiveness
11:40 Speaker’s Panel Session: Martin Armstrong, Associate Director, Translational
The Purpose, Benefits and Viability of Collaborations Medicine, Shire Pharmaceuticals
and Partnerships in Biobanking Today
In this interactive panel session, Speaker’s from this 16:50 Chairman’s Closing Comments
morning’s “Collaborations” section of the event will
take your questions – please come prepared to put your 17:00 Close of Day One
questions to the panel!
• Evaluating the role collaborations and partnerships play
• Discussing examples of existing successful partnerships
• Educating the public through collaboration in the media
Panellists:
George Dagher, Deputy Director, Clinical Research,
Very nice presentations with
INSERM and Leader of Funding & Financing at BBMRI
Frans van der Horst, Chair, Dutch Collaborative
spot on subjects. Very good sessions
Biobank
Bas de Jong, Biobank Manager, Erasmus MC Tissue Erasmus MC Tissue Bank
Bank and ISBER

3. Conference Day Two: 28th September 2011
08:30 Registration and Refreshments 12:20 Networking Lunch
09:00 Chairman’s Welcome 13:40 Assessing the Viability and Future of DNA Biobanking
in Today’s World
ENSURING HIGH QUALITY SAMPLE COLLECTION, STORAGE • Discussing whether DNA sample storage is still
AND RETRIEVAL TO FACILITATE MEDICAL RESEARCH important with the developments in today’s
sequencing and analytical technology
09:10 Keynote Session: Successfully Navigating the • Evaluating various storage techniques for DNA
Bioethical Complexities and Constraints of Sample samples
Collection and Management • Debating whether original informed consent covers
• Looking at the bigger picture: a global, social lack DNA collection and analysis
of data privacy • Discussing whether the patient should be informed
• Assessing how this wider attitude impacts the of other discovered conditions
biobanking world Amelia Warner, Head of Clinical Pharmacogenetics,
• Evaluating the regulatory constraints and gaps for Merck
biospecimen data privacy
• Discussing the effect new technology has had on UTLISING COST-EFFECTIVE PARTNERSHIPS TO ENHANCE
bioethics, and what this means for biobanking THE QUALITY OF PRODUCT DELIVERY
Ruth Chadwick, Council Member, HUGO and
Professor at Cardiff University 14:20 Research Biobanking as a Facilitator for Biomarker
Discovery
09:50 Getting it Right: Managing the Ethics of Biospecimen • Ensuring compliance and best practice with a solid
Use in Biomedical Research concept
• Navigating the “minefield” of informed consent • Dealing with the daily challenge of operations in a
• Understanding the expectations and obligations of fast changing environment - providing fit for
returning results to patients purpose samples just in time
• Commercialising outcomes from human • Improving collaboration between clinical academia,
biospecimens research biotechs and pharma industry by identifying
• Managing the public/private interface (or How I mutual win-wins
Learned to Stop Worrying and Love the Research) • Validating initial findings in translational research –
Nik Zeps, Research Group Leader, St John of God bed-to-benchside and back
Healthcare Arndt Schmitz, Senior Scientist, Bayer
Antje Stratmann, Scientist, Bayer
10:30 Networking Coffee Break
15:00 Networking Coffee Break
11:00 Creating a Thorough and Useful Consent Form to
Allow Future Use of Samples 15:30 Standards in Pre-Storage Sample Analytics and their
• Ensuring compliance with personal data Effect on Quality
protection regulations, including the EU • Research done to define quality factors associated
personal data protection directive and with the pre-acquisition phase
guidelines related to biomedical research and • Process changes in the pre-acquisition phase that
pharmacovigilance present themselves as barriers to
• Complying with human samples collection implementation of desired strategies
regulations, and international texts relating to • Impacts of lag times time between tissues being
biobanking without a blood supply and freezing
• Ensuring that samples and data can be re-used • Recommended analytics for repository samples
• Managing samples once collected: how should upon initial acceptance
they be coded? How can we manage consent Emma Donald, Senior Research Scientist,
withdrawal? AstraZeneca
Anne Bahr, Deputy R&D and Data Privacy Officer,
sanofi-aventis 16:10 Quality Control of Tissues: The Pathologist’s
Perspective
IMPROVING THE RUNNING OF YOUR BIOBANK THROUGH • Defining SOP’s in tissue collection and storage
EFFECTIVE LOGISTICS AND TECHNOLOGY • Assessing the quality and integrity of the tissues
• Aliquoting tissue samples and defining MTA
11:40 Bioethics Open Panel Discussion: Ensuring Good • Debating the pro’s and cons of FFPE vs. Frozen Tissues
Ethical Practice in Biobanking and Research Vincenzo Canzonieri, Co-Director, Pathology Dpt.
• Negotiating informed consent – reach, coverage & Resp. Biobank, National Cancer Institute 9Italy)
flexibility Lorenzo Memeo, Director, Pathology Dpt., Resp.
• Return to patients: should biobanks play an active Biobank, Mediterranean Institute of Oncology
role?
• Sample collection and analysis: evaluating good 16:50 Chair’s Closing Comments
ethical practice
• Topics from the Floor 17:00 Close of Main Conference
Panellists:
Ruth Chadwick, Council Member, HUGO and
Professor at Cardiff University
Nik Zeps, representative, Australian Health Ethics
Committee and the Ethics and Policy Great to have a day of
practical projects & big
Committee of the International Cancer Genome
Consortium
Bartha Knoppers, Director, Centre of Genomics
and Policy, McGill University and Canada
Research Chair in Law and Medicine
pharma. Extremely valuable
Chaired by the Chair of the Day
Genentech

4. Post-Conference Focus Day: 29th September 2011
Biomarkers & Personalised Healthcare
08:30 Registration and Refreshments
09:10 How Biobanking Enables Pre-Clinical Biomarker Validation
• Biomarker concepts - prognostic, pharmacodynamic and predictive markers and their respective value and sample needs
• Utilising central biobanking as enabling technology supporting a project portfolio
• Successfully validating pre-clinical biomarker assays for the clinic, what can animal models contribute
• Establishing fruitful collaborations with biotechs and academic clinicians providing today’s gold standard of care
• The new holy grail for pharma oncology development projects - circulating tumor cells?
Arndt Schmitz, Senior Scientist, Bayer
Antje Stratmann, Scientist, Bayer
09:50 The Importance of Biomarkers: Facilitating Drug Discovery and Development
• Evaluating the importance of biomarkers in today’s research
• Highlighting how biomarker discovery can be aided by effective biobanking
• Discussing the role of biomarkers in translational medicine
• Overcoming the major hurdles of biomarker discovery and validation
Vincenzo Canzonieri, Co-Director, Pathology Dpt., Resp. Biobank, National Cancer Institute (Italy)
Lorenzo Memeo, Director, Pathology Dpt., Resp. Biobank, Mediterranean Institute of Oncology
Agostino Steffan, Director Clinical Pathology Unit, National Cancer Institute (Italy)
10:30 Networking & Refreshments
11:00 Effective Analysis of Tumour Samples for Personalised Healthcare and Biomarkers:
a User Case Study
• Evaluating what benefits personalised healthcare approaches have brought to oncology patients
• Identifying the key difficulties in biomarker analysis in oncology
• Emphasising how important biobank accessibility and access to samples is solving these difficulties
• Using new technology to reduce the occurrence of similar challenges in the future
Gillian Ellison, Tumour Genetics Capability Manager, AstraZeneca
11:40 Panel Discussion: Biomarkers, Biobanking and Collaborations
In this interactive panel session, Speaker’s from today’s biomarker and personalised healthcare focus day
will take your questions – please come prepared to put your questions to the panel!
• Discussing the role biobanking plays in biomarker research
• Identifying how biobanks could facilitate research
• Overcoming common hurdles in biomarker discovery & validation
• Translating biomarkers into the clinic
Panellists:
Arndt Schmitz, Senior Scientist, Bayer
Gillian Ellison, Tumour Genetics Capability Manager, AstraZeneca
Amelia Warner, Head of Clinical Pharmacogenetics, Merck
12:20 Networking Lunch
13:40 The Role of Companion Diagnostics and Personalised Healthcare in Drug Development:
Improving Efficacy and Reliability
• Discussing the role companion diagnostics can play in drug development
• Assessing the advantages and disadvantages of using companion diagnostics
• Incorporating companion diagnostics seamlessly into pre-clinical development
• Evaluating the clinical viability
Amelia Wall Warner, Head of Clinical Pharmacogenomics, Merck
14:20 Biomarkers as a Gateway to Personalised Medicine
• Assessing what stage we are at in the journey towards personalised healthcare
• Discussing the impact of the change from blockbuster drugs to patient-centric healthcare
• Analysing the importance and use of stratified trials and medicine
• Highlighting how biomarker research (and thus biobank sample quality) is key
Birgitte Søgaard, Divisional Director, Clinical Pharmacology and Translational Medicine, Lundbeck
15:00 Close of Focus Day
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk

5. Sponsors & Exhibitors
www.marken.com www.KBioscience.co.uk
Founded in 1980, Marken is focused on supporting the premium logistics of Pharmaceutical, Biotechnology KBioscience is a UK based technology company with one business
and clinical service companies. Through our strategically placed offices we manage the collection, transport unit focused on Drug Discovery products, including Covaris Adaptive
of specimens, and distribution of temperature sensitive clinical trial supplies. Additionally through our depot Focused Acoustics (AFA) technology. Adaptive Focused Acoustics
network we support the storage and distribution of life science assets. Our team members and network of (AFA) technology empowers many scientific disciplines to develop new
facilities bridge the distance between patients and the essential resources of life science companies. processes using isothermal and non-contact processes, including
acoustic homogenization and acoustic dissolution. Main applications for
Marken understands the specialized and dynamic needs of our industry; we retain our global agility by the AFA technology are Compound Dissolution, (Pre-)Formulation and
continuously investing in our people, technologies and global installations to better support our clients. tissue disruption (AMDEtox, DMPK, RNA and biomarker extraction).
People With over 400 people in 25 offices spanning the world, Marken has the expertise to ship globally and In Compound management AFA offers greatly improved dissolution
deliver locally to investigator sites or directly to patients. speeds and standardizes the dissolution process. In Screening AFA
can drastically improve compound re-dissolution and lowering CV’s by
Technologies Our state of the art management, tracking and information systems are second to none efficient assay mixing. KBiosciences further offers several technologies
offering our clients real time visibility to the last mile. From hand to hand our chain of custody reflects our for sealing, piercing and cutting of seals and plates. Products are
dedication to supporting and exceeding our client’s expectations. standard heat- and pressure sealers, as well as special laser sealing
(pre)piercing and cutting machines.
The combination of Expertise, Agility, and Resources are complemented by our dedication to supporting
our clients, their patients and the many lives that depend on our services. Company general contact details:
Unit 7, Maple Park, Essex road, Hoddesdon, EN11 0EX, United Kingdom
Company general contact details: Tel +44 (0) 1992 470 757
Unit 3, Hogarth Business Park, Burlington Lane, Chiswick, London W4 2TX, United Kingdom Fax +44 (0) 8700 511302
Tel: +44 203 249 7400 info@KBioscience.co.uk
Fax: +44 203 249 7322
Media Partners Sponsorship & Exhibition Opportunities
Maximise Your Involvement: Sponsorship and
Exhibition Opportunities
The biomolecular screening portal
Pharma IQ’s Global Pharmaceutical Global Biobanking
2011 is attended by senior officials and decision-makers
from industry, academia, institutes and national biobanks,
bringing together buyers and suppliers in one location. In
addition to this, Global Biobanking is the only Conference in
Who Should Attend? Europe to partner with ISBER.
Senior Vice President, Vice President, Focused and high-level, the event will be an excellent
Executive Director, Director, Associate platform to initiate new business relationships. With
tailored networking, sponsors can achieve the face-to-face
Director, Head and Manager from: contact that overcrowded trade shows cannot deliver.
• Independent Biobanks • Pharmacogenomics
Exhibiting and Sponsorship options are extensive, and
• Pharmaceutical • Pathology
• Biotech • Genomics
packages can be tailor-made to suit your individual
• Medical Research Institute • Translational Medicine company’s needs. Most packages include complimentary
• Academia • Personalised Medicine entry passes, targeted marketing to industry officials and
• Related government officials • Lab Management executives, and bespoke networking opportunities.
In the following departments: • Inventory Management
• Research & Development • Molecular Technologies Other features of sponsorship include:
• Biobanking • Biologics Research
• Biorepository • Data Privacy/Protection/ • Prominent exhibition space in the main conference
• Biological Sample Security Officers networking area
Management • Quality Control and Quality • Participation in comprehensive pre-event marketing
• Biosample Management Management campaigns
• Tailored marketing strategies to suit your organisation’s
size, capabilities and individual requirement
About Pharma IQ
For more information and to discuss the right opportunity,
contact Gal Cohen on +44 (0)207 368 9300 or sponsorship@
iqpc.co.uk
Continue your learning experience with Pharma IQ online. As well as
playing host to a series of global events where leading industry experts
and thought leaders share their experience, knowledge and strategic
thoughts, Pharma IQ also offers an online community for pharma &
biotech professionals. Join now to network with your peers and access
exclusive videos, podcasts and presentations from this and other
Pharma IQ events.
Join the community: http://Pharma-IQ.com/join.cfm
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk

6. Global Biobanking 2O11 5 WAYS TO REGISTER
Freephone: 0800 652 2363 or
Conference: 27th-28th September
Biomarkers & Personalised Healthcare Focus Day: 29th September +44 (0)20 7368 9300
Venue: Thistle Marble Arch, London, UK Fax: +44 (0)20 7368 9301
To speed registration, please provide the priority code located on the mailing label or in the box below. Post: your booking form to
My registration code is: PDFW IQPC Ltd. 129 Wilton Road,
Please contact our database manager on +44(0) 207 368 9300 or at database@iqpc.co.uk quoting the registration code above to London SW1V 1JZ
inform us of any changes or to remove your details.
Online: www.globalbiobanking.com
Academia and Biobanks Email: enquire@iqpc.co.uk
Packages Register and Pay by Register and Pay by Register and Pay by Standard Price
1st July* 29th July* 2nd September*
Conference + Focus Day
£748+VAT £798+VAT £848+VAT £998+VAT Join our Global Biobanking event on
Save £250 Save £200 Save £150
http://events.linkedin.com/Global-Biobanking-2011/pub/695032
£499+VAT £549+VAT £599+VAT £699+VAT
Conference Only
Save £ 200 Save £150 Save £100
Focus Day Only £299+VAT £299+VAT £299+VAT £299+VAT
Team Discounts*
Industry IQPC recognises the value of learning in teams. Groups of 3 or more
Packages Register and Pay by Register and Pay by Register and Pay by Standard Price booking at the same time from the same company receive a 10%
1st July* 29th July* 2nd September*
discount. 5 or more receive a 15% discount. 7 receive a 20% discount.
£1,098+VAT £1,198+VAT £1,298+VAT £1,498+VAT
Conference + Focus Day
Save £400 Save £300 Save £200
Only one discount available per person.
£799+VAT £899+VAT £999+VAT £1,099+VAT
Conference Only
Save £ 300 Save £200 Save £100 Venue & Accommodation
Focus Day Only £399+VAT £399+VAT £399+VAT £399+VAT VENUE:
Thistle Marble Arch
Solution Providers Bryanston Street, Marble Arch, London W1H 7EH
Packages Register and Pay by Register and Pay by Register and Pay by Standard Price
1st July* 29th July* 2nd September*
Phone: 0871 376 9027 Fax: 0871 376 9127
ACCOMMODATION:
£1,798+VAT £1,848+VAT £1,898+VAT £2,048+VAT
Conference + Focus Day
Save £250 Save £200 Save £150 For Thistle Marble Arch Tel: +44 (0)871 376 9027 select option 1,
£1,399+VAT £1,449+VAT £1,499+VAT £1,599+VAT or email: reservationsadmin.marblearch@guoman.co.uk . Always
Conference Only
Save £ 200 Save £150 Save £100 quote promotional code GA1. Prices from £130 + vat including
Focus Day Only £449+VAT £449+VAT £449+VAT £449+VAT breakfast. Or for a further selection of London. hotels search
www.4cityhotels.com
*To qualify for discounts, payments must be received by the early bird registration deadline. Early booking discounts are not valid in conjunction with any other offer.
UK VAT is charged at 20%. VAT Registration # GB 799225967
Free Online Resources
To claim a variety of articles, podcasts and other free resources please
Delegate Details visit www.globalbiobanking.com
Please photocopy for each additional delegate
6 Mr 6 Mrs 6 Miss 6 Ms 6 Dr 6 Other Digital Conference On CD-ROM
First Name Family Name A digital version of the conference proceedings, including all
presentations, is available to buy.
Job Title
6 I cannot attend the event, please send me the CD Rom priced at
Tel No. £599 plus VAT
Email Recent digital conferences available - £599 plus VAT each
6 Yes I would like to receive information about products and services via email 6 Biobanking 2009
Organisation 6 Compound Management 2009
Nature of business 6 Disposables for Biomanufacturing 2009
6 Cool Chain Europe 2010
Address
Postcode Country Please send me conference materials indicated above.
Telephone Fax I have filled out credit card details below
Approving Manager
For further information
Name of person completing form if different from delegate: Please call: 0207 368 9300
or email: knowledgebank@iqpc.co.uk.
Signature
I agree to IQPC’s cancellation, substitution and payment terms Terms and Conditions
Special dietary requirements: 6 Vegetarian 6 Non-dairy 6 Other (please specify) Please read the information listed below as each booking is subject to IQPC Ltd standard terms and conditions.
Return of this email will indicate that you accept these terms.
Please indicate if you have already registered by Phone 6 Fax 6 Email 6 Web 6
Payment Terms Upon completion and return of the registration form full payment is required no later than 5
Please note: if you have not received an acknowledgement before the conference, please call us to confirm your booking. business days from the date of invoice. Payment of invoices by means other than by credit card, or purchase
order (UK Plc and UK government bodies only) will be subject to a £49 (plus VAT) per delegate processing fee.
Payment must be received prior to the conference date. We reserve the right to refuse admission to the confer-
Payment Method ence if payment has not been received.
IQPC Cancellation, Postponement and Substitution Policy You may substitute delegates at any time by
providing reasonable advance notice to IQPC. For any cancellations received in writing not less than eight (8)
Total price for your Organisation: (Add total of all individuals attending): days prior to the conference, you will receive a 90% credit to be used at another IQPC conference which must
occur within one year from the date of issuance of such credit. An administration fee of 10% of the contract fee
Card Number: VISA 6 M/C 6 AMEX 6 will be retained by IQPC for all permitted cancellations. No credit will be issued for any cancellations occurring
within seven (7) days (inclusive) of the conference.
6666666666666666 In the event that IQPC cancels an event for any reason, you will receive a credit for 100% of the contract fee paid.
You may use this credit for another IQPC event to be mutually agreed with IQPC, which must occur within one
year from the date of cancellation.
Exp. Date: 6 6 6 6 Sec: 6 6 6 6
Conference code 13647.004
In the event that IQPC postpones an event for any reason and the delegate is unable or unwilling to attend in
on the rescheduled date, you will receive a credit for 100% of the contract fee paid. You may use this credit
for another IQPC event to be mutually agreed with IQPC, which must occur within one year from the date of
Name On Card: Signature: postponement.
Except as specified above, no credits will be issued for cancellations. There are no refunds given under any
circumstances.
Billing Address (if different from below):
IQPC is not responsible for any loss or damage as a result of a substitution, alteration or cancellation/postpone-
ment of an event. IQPC shall assume no liability whatsoever in the event this conference is cancelled, resched-
City/County/Postcode Cheque enclosed for: £ (Made payable to IQPC Ltd.) uled or postponed due to a fortuitous event, Act of God, unforeseen occurrence or any other event that renders
performance of this conference impracticable, illegal or impossible. For purposes of this clause, a fortuitous
event shall include, but not be limited to: war, fire, labour strike, extreme weather or other emergency.
Please note that while speakers and topics were confirmed at the time of publishing, circumstances beyond the
(Please quote 13647.004 with remittance advice) control of the organizers may necessitate substitutions, alterations or cancellations of the speakers and/or topics.
As such, IQPC reserves the right to alter or modify the advertised speakers and/or topics if necessary without any
IQPC Bank Details: HSBC Bank, 67 George Street, Richmond Surrey, TW9 1HG. Sort Code: 40-38-18 Account No: 51304143 Swift liability to you whatsoever. Any substitutions or alterations will be updated on our web page as soon as possible.
Code: MIDLGB2112V IBAN Code: GB59MIDL40381851304143
Account Name: International Quality & Productivity Centre Ltd. Discounts All ‘Early Bird’ Discounts require payment at time of registration and before the cut-off date in order
to receive any discount. Any discounts offered whether by IQPC (including team discounts) must also require
payment at the time of registration. All discount offers cannot be combined with any other offer
PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE